Posted on August 18, 2026 by Sunny Singh
You got the clearance. Maybe it was a 510(k), maybe a De Novo, maybe you’re through a brutal PMA cycle. The clinical data is strong. Physicians who’ve seen the product are enthusiastic. Your investors are expecting the revenue curve to start bending upward.
And then it doesn’t.
The pipeline looks busy but nothing is closing at the rate you forecasted. Deals drag. Champions inside hospitals go quiet for weeks. Your sales team keeps telling you they need “more time” or “better leads” or “a different comp plan.” Meanwhile, you’re burning through runway and your board is starting to ask questions that sound a lot less like encouragement and a lot more like concern.
This is the moment where most medtech CEOs start looking for the wrong fix. They assume the problem is execution at the rep level, or product-market fit, or pricing. Sometimes those things need attention. But more often, the real issue is structural. The go-to-market architecture itself has bottlenecks that are invisible from the top of the org chart but painfully obvious from the perspective of the buyer.
Here’s where those bottlenecks actually live.
The most common and most expensive GTM bottleneck in medtech is timing. Specifically, the decision to wait until after regulatory clearance to build commercial infrastructure.
This feels rational. Why invest in sales, marketing, and market access before you have a cleared product? The answer is that hospital buying cycles in medtech are extraordinarily long. Industry experts consistently estimate the average medical device sales cycle at around eight months for standard purchases, and for capital equipment or anything that touches surgical workflow, it can stretch well beyond a year. Health Launchpad, a firm that advises healthtech companies on hospital selling, has documented individual sales cycles lasting as long as six years from initial contact to signed contract.
That means every month of commercial delay after clearance is a month of zero revenue on a product that’s already cost you millions to develop. Companies that wait to build the GTM engine until the device is cleared are effectively adding 6 to 18 months of additional delay on top of an already long cycle.
The companies that avoid this bottleneck start commercial planning in parallel with regulatory preparation. They’re building the clinical value narrative, mapping the hospital buying process, identifying early target accounts, and developing stakeholder-specific content while the submission is still in progress. By the time clearance comes through, they’re not starting from scratch. They’re activating a system that’s already been designed.
Here’s a pattern I see constantly in high-growth medtech companies. The CEO or founder can walk into a room with a surgeon, have a 45-minute conversation, and walk out with a clinical champion. The clinical story is compelling when it comes from the person who lived it.
The problem is that the way most medtech companies translate that founder narrative into commercial materials is through a process that strips out everything that made it work. The passion, the clinical nuance, the ability to speak to a specific physician’s workflow concerns. What comes out the other end is a set of generic claims about “improving patient outcomes” and “reducing procedure time” that sound identical to every other device in the category.
This is a messaging bottleneck, and it creates downstream problems that most leadership teams misdiagnose as sales execution issues. When your reps can’t clearly articulate why your device is different in a way that resonates with each stakeholder in the buying process, deals slow down. When your marketing materials don’t address the specific concerns of the value analysis committee, the deal stalls at a stage your CRM wasn’t even designed to track.
The fix requires building what I call a stakeholder-specific value architecture. This means developing distinct messaging tracks for each decision-maker in the hospital buying chain: the clinical champion, the department head, supply chain and procurement, finance, and the C-suite. Each of these stakeholders defines value differently, tolerates risk differently, and needs to hear a different version of your story.
McKinsey’s research on medtech commercial capabilities reinforces this. Their analysis of more than 60 medtech companies found that companies with the most advanced commercial capabilities grew at a rate 1.4 times higher than companies with average capabilities. One of the key differentiators they identified was buyer-segmented value communication, which is exactly the kind of stakeholder-specific messaging most early-stage medtech companies never build.
There’s a specific kind of deal death in medtech that doesn’t show up in your pipeline reporting. The deal doesn’t get rejected. It doesn’t go to a competitor. It just stops moving. The physician champion is still enthusiastic. The department head signed off months ago. But the deal sits in some administrative purgatory where nobody is explicitly saying no and nobody is moving forward.
Nine times out of ten, this is a market access problem masquerading as a sales problem.
The bottleneck is usually one of three things: reimbursement ambiguity, a gap in the health economic evidence, or a misalignment between how your company talks about cost and how the hospital system actually evaluates financial risk.
Reimbursement is the one that trips up the most companies. Having a CPT code or a coverage policy that theoretically applies to your device is not the same as having a clear, predictable reimbursement pathway for your customer. If there is ambiguity about coverage criteria, prior authorization requirements, or expected payment rates, that ambiguity becomes the hospital’s risk. And hospitals are not in the business of absorbing reimbursement risk on behalf of a vendor they’ve known for six months.
The medtech companies that clear this bottleneck do something that sounds simple but that very few actually execute: they build reimbursement support tools and payer strategy documentation that their sales team can put in front of a hospital CFO or revenue cycle director. Not a slide that says “reimbursement available.” An actual resource that walks through payer-by-payer coverage status, expected payment ranges, prior authorization requirements, and appeal pathways. This removes the risk from the buyer’s side of the table and puts it back where it belongs: on yours.
This is becoming even more critical in 2026. With Medicare and Medicaid budget pressures mounting, hospital systems are scrutinizing new technology purchases with more financial rigor than ever. The medtech companies that make it easy for hospitals to model the economic impact of adoption will close deals faster than those that leave the financial story for the buyer to figure out.
In most medtech companies under $50M in revenue, marketing and sales operate as two separate functions that happen to share a CRM login. Marketing produces content that sales doesn’t use. Sales provides feedback that marketing doesn’t act on. And nobody has a shared definition of what a qualified lead actually means in the context of hospital selling.
This misalignment creates a bottleneck that compounds over time. Marketing generates awareness-level interest from clinical audiences, but the leads that get passed to sales aren’t mapped to where those contacts sit in the hospital buying process. A surgeon who downloaded a white paper is not the same as a hospital system with an active need, a budget cycle that aligns with your timeline, and a value analysis committee that’s open to evaluating new technology.
The fix isn’t just a service-level agreement between marketing and sales, although that helps. The real fix is building a shared commercial model that both teams operate within. That means agreeing on ideal customer profile criteria that go beyond clinical fit and include institutional readiness signals: Is this hospital part of an IDN that’s consolidating vendors? Is their current contract with an incumbent up for renewal? Have they recently expanded a service line that aligns with your device’s clinical application?
Research from Map My Customers found that companies with a defined, shared sales process see 18% more revenue growth on average than those without one. In medtech, where the buying process is already complex and multi-layered, that alignment gap becomes even more costly. Sales reps spend less than 36% of their time actually selling, according to industry benchmarks. In medtech, where every interaction needs to be clinically credible and stakeholder-appropriate, wasted time isn’t just inefficient. It’s lost pipeline.
Most medtech CEOs understand that clinical evidence matters. Fewer understand how to deploy clinical evidence as a commercial asset rather than just a regulatory requirement.
The bottleneck shows up when your clinical data is strong enough to support clearance but not structured in a way that supports adoption. Value analysis committees don’t evaluate your device based on the same endpoints the FDA reviewed. They want outcomes data that maps to their institutional priorities: length of stay, readmission rates, complication rates, total cost of care. If your published studies don’t speak to those metrics, you’re asking the VAC to make an inferential leap that most committees are unwilling to make.
This is where the gap between clinical affairs and commercial strategy becomes a growth problem. Clinical teams are typically focused on generating evidence that supports the regulatory submission and peer-reviewed publication. Commercial teams need that evidence repackaged into formats that serve the buying process: health economic models, cost-comparison tools, and outcomes summaries that a non-clinical committee member can evaluate in 15 minutes.
McKinsey’s work on medtech value creation supports this observation. Their research notes that the need for clinical data to drive product adoption is no longer reserved for a few select devices, and that top medtech performers are borrowing analytical tools from the pharmaceutical industry to improve clinical evidence generation and deployment.
The companies that close this bottleneck treat clinical evidence as a living commercial asset. They’re continuously updating their evidence package with post-market data, building institution-specific ROI models, and training their commercial teams to present clinical data in the language that each stakeholder in the buying process actually speaks.
The consolidation of hospital systems into large Integrated Delivery Networks has fundamentally changed how medical devices get purchased. Yet most medtech GTM strategies are still designed as if they’re selling to individual hospitals.
Definitive Healthcare’s 2025 data shows that the top five health systems in the US collectively generate close to $160 billion in net patient revenue. When a company like HCA, CommonSpirit, or Kaiser Permanente makes a purchasing decision, that decision cascades across dozens or hundreds of facilities. Winning one of those contracts is transformational. But the process for getting there is completely different from selling to a standalone community hospital.
Most high-growth medtech companies underinvest in IDN strategy because they’re still operating with a field-sales model optimized for individual facility relationships. They don’t have the strategic account management infrastructure, the system-level economic modeling, or the corporate-level clinical narrative needed to compete at the IDN level.
This is a bottleneck that doesn’t become visible until you’ve hit the ceiling on individual facility sales and need system-wide contracts to reach your next revenue milestone. By then, you’re already 12 to 18 months behind the companies that started building IDN capabilities earlier.
Every medtech company has multiple GTM bottlenecks, but they don’t all carry equal weight. The question for a CEO is which bottleneck is creating the most drag on growth right now, and which one will create the most drag 12 months from now.
A diagnostic framework that works: look at where deals are dying or stalling in your pipeline and map those failure points to the bottleneck categories above. If deals are stalling after clinical champion engagement, you likely have a stakeholder messaging gap or a market access problem. If deals are dying at the VAC stage, your clinical evidence isn’t structured for the buying process. If you’re winning one-off facility deals but can’t break into system-wide contracts, your IDN strategy is the constraint. If your pipeline is thin despite strong clinical interest, your marketing and sales alignment is the issue.
The medtech companies that sustain growth past early traction are the ones that diagnose these bottlenecks honestly and invest in fixing them before the board forces the conversation. That usually means bringing in commercial leadership that has navigated these specific challenges before, whether that’s a full-time commercial hire or a fractional leader who can architect the GTM infrastructure while you scale.
The most common GTM bottlenecks in medtech include delayed commercial planning (building GTM infrastructure after regulatory clearance instead of in parallel), messaging that doesn’t differentiate across hospital stakeholders, reimbursement ambiguity that creates buyer risk, misalignment between marketing and sales on lead qualification and account targeting, clinical evidence that’s structured for regulatory approval but not for the hospital buying process, and a lack of IDN-level selling strategy. These bottlenecks compound over time and are often misdiagnosed as sales execution problems.
Medical device companies frequently struggle to scale after clearance because the hospital buying process is fundamentally different from the regulatory process. Clearance proves safety and efficacy. Adoption requires addressing a completely different set of concerns: institutional economics, reimbursement predictability, workflow integration, supply chain compatibility, and competitive differentiation. Companies that treat clearance as the starting line for commercial activity are already behind, because hospital sales cycles average eight months or more.
The average medical device sales cycle is approximately eight months for standard purchases, according to industry experts. Capital equipment and devices with significant procedural or workflow implications can take 12 to 18 months or longer. In some cases, particularly with large health systems or IDNs, the full cycle from initial contact to signed contract can extend to multiple years. The length is driven by multi-stakeholder decision-making, value analysis committee reviews, competitive evaluation processes, and budget cycle alignment.
A value analysis committee (VAC) is a cross-functional group within a hospital or health system that evaluates new technology purchases. The VAC typically reviews clinical evidence, health economic data, reimbursement viability, supply chain considerations, and comparative cost data before approving a new device for use. VAC requirements represent a significant GTM bottleneck for medtech companies that haven’t built evidence packages and cost-comparison tools specifically designed for this audience.
Fixing a broken medtech GTM strategy starts with diagnosing where deals are stalling or dying in the pipeline and mapping those failure points to specific bottleneck categories: messaging, market access, sales and marketing alignment, clinical evidence deployment, or IDN strategy. From there, the fix typically involves building stakeholder-specific value messaging, developing reimbursement support tools, aligning marketing and sales around a shared commercial model with institutional readiness criteria, and restructuring clinical evidence for the buying process rather than just the regulatory process.
Most medtech commercialization failures stem from underestimating the complexity of the hospital buying environment. The device may have strong clinical merit, but the commercial infrastructure around it was built too late, built for the wrong audience, or never built at all. Common failure patterns include generic messaging that doesn’t address individual stakeholder concerns, reimbursement ambiguity that creates institutional risk, and a lack of alignment between clinical evidence and the economic data that hospital decision-makers actually need.
A fractional CMO for a medical device company provides senior commercial and marketing leadership on a part-time or project basis. This typically includes auditing and rebuilding the go-to-market strategy, developing stakeholder-specific clinical and economic messaging, building market access and hospital adoption frameworks, aligning marketing and sales operations, and creating the commercial infrastructure needed to support scalable growth. It’s particularly valuable for medtech companies between $3M and $50M in revenue that need experienced strategic leadership but aren’t ready for a full-time C-suite marketing hire.
Want to talk through which GTM bottleneck is creating the most drag on your growth? I work with high-growth medtech companies as a fractional CMO, helping leadership teams identify and fix the commercial infrastructure gaps that stall scale.
If your positioning, your campaigns, and your reporting need to work as one system, and you want someone who's built that inside healthcare before, let's talk.
Book a 20-minute discovery call